Skip Navigation


JAC Advance Access originally published online on April 25, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/6/1327    most recent
dkg240v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Macchi, B.
Right arrow Articles by Mastino, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macchi, B.
Right arrow Articles by Mastino, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 1327-1330
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro

Beatrice Macchi1,2,*, Emanuela Balestrieri3 and Antonio Mastino3

1 Department of Neuroscience, University of Rome ‘Tor Vergata’, Via Montpellier 1, 00133 Rome; 2 IRCCS S.Lucia, Rome; 3 Department of Microbiological, Genetic and Molecular Science, University of Messina, Messina, Italy

Keywords: HTLV-1, antiviral, in vitro

The first 150 words of the full text of this article appear below.

Human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection is nowadays considered a global epidemic since 10–20 million individuals are estimated to be carriers of the virus and the risk of developing disease in endemic areas has been evaluated as 5% in asymptomatic patients. HTLV-1 is endemic in south-western Japan, in the Caribbean basin, where 3–4% of the population is seropositive for the virus, in North and South America and in some areas of Africa. The main modalities of transmission are: (i) perinatally, mainly breast feeding; (ii) parenterally, blood transfusion and sharing of needles and syringes infected with contaminated blood in drug abusers; and (iii) sexual contacts.1 HTLV-1 is associated with a variety of clinical diseases. Initially it was linked to a chronic adult T cell leukaemia/lymphoma (ATLL), and, later, to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), both found in endemic areas of Japan and of Central and South America. ATLL . . . [Full Text of this Article]


   HTLV-1 infection in vitro
 

   Conclusions
 

   Acknowledgements
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
H. Eizert, P. Bander, P. Bagossi, T. Sperka, G. Miklossy, P. Boross, I. T. Weber, and J. Tozser
Amino Acid Preferences of Retroviral Proteases for Amino-Terminal Positions in a Type 1 Cleavage Site
J. Virol., October 15, 2008; 82(20): 10111 - 10117.
[Abstract] [Full Text] [PDF]